Physician profile
Jun Yang Jiang
NPI 1447792171
$772.69
in general payments reported to CMS, 2019-2025
10 companies · $334 in 2025
The $334 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $115 · 2023: $123 · 2024: $202 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.05 |
| Education | $174.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $199.81 | 2023-2024 | Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $146.19 | 2025 | Yeztugo |
| Vertex Pharmaceuticals Incorporated | $124.50 | 2025 | |
| Lilly USA, LLC | $114.70 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $54.99 | 2024 | Enhertu |
| Genentech USA, INC. | $35.77 | 2025 | Columvi |
| Pharmaessentia USA Corporation | $31.95 | 2023 | Besremi |
| Coherus Oncology, INC. | $27.13 | 2025 | Loqtorzi |
| Array Biopharma INC | $19.31 | 2024 | Mektovi, Xalkori, Lorbrena |
| Eisai INC. | $18.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Yang Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.